

Registration Assessment Sample Papers 2013
Answers and Guidance

Closed Book

Question	Answer	Guidance
1	B	See BNF Appendix 1 and 'Stockley's Drug Interactions'.
2	A	The clinicians' section of Patient.co.uk provides a summary at: http://www.patient.co.uk/doctor/Different-Levels-of-Evidence-(Critical-Reading).htm
3	C	See BNF Section 6.1.2
4	C	Principles for Best Practice in Clinical Audit are available at http://www.nice.org.uk/media/796/23/bestpracticeclinicalaudit.pdf See PSNC guide on the audit cycle in the context of the community pharmacy contract. http://www.psn.org.uk/data/files/PharmacyContractandServices/ClinicalGovernance/a_guide_to_clinical_audit.pdf
5	C	The clinicians' section of Patient.co.uk provides a useful summary of presenting symptoms, including a section on management at: http://www.patient.co.uk/doctor/Migraine-Management.htm See individual product monographs at: http://www.medicines.org.uk/emc/
6	C	The clinicians' section of Patient.co.uk provides a summary of presenting symptoms at: http://www.patient.co.uk/doctor/diabetes-mellitus
7	B	The clinicians' section of Patient.co.uk provides a useful summary of presenting symptoms, including a section on management at: http://www.patient.co.uk/doctor/Herpes-Simplex-(Oral).htm
8	D	See Human Medicines Regulations 2012 (SI 2012/1916) at: http://www.legislation.gov.uk/uksi/2012/1916/pdfs/uksi_20121916_en.pdf
9	E	Guidance on the management of dispensing errors is available from the GPhC in Responding to Complaints and Concerns. Guidance Note September 2012, available at: http://www.pharmacyregulation.org/sites/default/files/Responding%20to%20complaints%20and%20concerns%20g.pdf
10	C	See BNF Section 5.5.1.
11	C	See Human Medicines Regulations 2012 (SI 2012/1916) at: http://www.legislation.gov.uk/uksi/2012/1916/pdfs/uksi_20121916_en.pdf Alternative sources of information include Medicines, Ethics and Practice The professional guide for pharmacists. Edition 36 July 2012 or http://www.dhsspsni.gov.uk/gmgr-retention-pharmacy-records.pdf
12	E	The clinicians' section of Patient.co.uk provides a summary of presenting

Question	Answer	Guidance
		symptoms, available at: http://www.patient.co.uk/doctor/Vaginal-and-Vulval-Candidiasis.htm
13	D	See BNF section 7.2.2.
14	E	The Drug Tariff England and Wales is available at: http://www.ppa.org.uk/ppa/edt_intro.htm The Drug Tariff Scotland is available at: http://www.isdscotland.org/Health-Topics/Prescribing-and-Medicines/Scottish-Drug-Tariff/
15	B	The Drug Tariff England and Wales is available at: http://www.ppa.org.uk/ppa/edt_intro.htm The Drug Tariff Scotland is available at: http://www.isdscotland.org/Health-Topics/Prescribing-and-Medicines/Scottish-Drug-Tariff/
16	A	See BNF Section 5.1.1
17	C	See BNF Section 5.1.3
18	E	See BNF Section 5.1.6
19	A	See BNF section 3.1.3
20	D	See BNF Section 2.5.5.1
21	B	See BNF Guidance on prescribing: Extemporaneous preparation
22	E	See BNF Guidance on prescribing: Extemporaneous preparation
23	D	See BNF Guidance on prescribing: Controlled Drugs and drug dependence.
24	C	See BNF Guidance on prescribing: Controlled Drugs and drug dependence.
25	E	Guidance on the management of dispensing errors is available from the GPhC in Responding to Complaints and Concerns. Guidance Note September 2012, available at: http://www.pharmacyregulation.org/sites/default/files/Responding%20to%20complaints%20and%20concerns%20g.pdf Further information on root cause analysis is available from the National Patient Safety Agency at: http://www.nrls.npsa.nhs.uk/rca/
26	C	See GPhC Standards of conduct, ethics and performance, and GPhC Guidance on patient confidentiality, available at: http://www.pharmacyregulation.org/standards/conduct-ethics-and-performance and http://www.pharmacyregulation.org/sites/default/files/Guidance%20on%20Confidentiality_April%202012.pdf
27	D	See GPhC CPD Standards at: http://www.pharmacyregulation.org/education/continuing-professional-development/cpd-standards

Question	Answer	Guidance
28	A	Information is available from the Health and Safety Executive at: http://www.hse.gov.uk/index.htm
29	E	See BNF Guidance on prescribing: Prescription writing
30	D	The clinicians' section of Patient.co.uk provides a useful summary of the condition including red flag symptoms http://www.patient.co.uk/doctor/Acute-Diarrhoea-in-Adults.htm
31	A	See BNF Section 2.8: Prophylaxis of venous thromboembolism
32	B	A glossary of terms is available at: http://www.cochrane.org/glossary
33	B	See BNF Section 4.7.2
34	D	Information is available at: http://www.patient.co.uk/doctor/Promoting-Prevention-and-Barriers-to-Prevention.htm
35	C	See BNF Section 7.3.5
36	C	Guidance on the management of insect bites and stings is available at: http://www.patient.co.uk/doctor/insect-bites-and-stings See BNF Emergency treatment of poisoning: Insect stings and Section 3.4.1 See individual product monographs at: http://www.medicines.org.uk/emc/
37	B	See GPhC Guidance for Responsible Pharmacists, available at: http://www.pharmacyregulation.org/sites/default/files/GPhC%20Responsible%20pharmacist%20guidance.pdf
38	C	See GPhC Guidance for Responsible Pharmacists, available at: http://www.pharmacyregulation.org/sites/default/files/GPhC%20Responsible%20pharmacist%20guidance.pdf
39	B	See BNF Section 2.8.2
40	A	Information on reporting adverse incidents involving medical devices is available from the Medicines and Healthcare products Regulatory Agency (MHRA) at: http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Devices/index.htm
41	A	See BNF Section 3.9.1
42	D	Using the given formula, in 300 mL Gentian Mixture, Alkaline, BP there will be $5 \times 30 = 150$ mL double strength chloroform. Concentrated chloroform water is 20 times more concentrated than double strength chloroform \therefore 7.5 mL concentrated chloroform water required.
43	A	See GPhC Standards for registered pharmacies, available at: http://www.pharmacyregulation.org/standards/standards-registered-pharmacies See GPhC Guidance for Responsible Pharmacists, available at: http://www.pharmacyregulation.org/sites/default/files/GPhC%20Responsible%20pharmacist%20guidance.pdf

Question	Answer	Guidance
44	C	See BNF Section 13.4
45	C	See BNF for Children

**Registration Assessment Sample Papers 2013
Answers and Guidance**

Open Book

Question	Answer	Guidance
1	A	See BNF Appendix 1.
2	B	See BNF for Children Section 4.1.1 Chloral Hydrate.
3	C	See BNF Guidance on prescribing: Prescribing in Palliative Care.
4	B	See BNF Section 2.8.2 Oral anticoagulants
5	D	See BNF Cardiovascular Risk Prediction Charts.
6	C	See BNF for Children Section 3.1.
7	B	See BNF for Children Section 3.1.
8	E	See BNF Section 10.1.1.
9	C	See BNF for Children Section 9.5.3.
10	D	See BNF Appendix 1.
11	C	See individual monographs in the BNF.
12	E	See individual monographs in the BNF.
13	B	See individual monographs in the BNF.
14	B	See individual monographs in the BNF.
15	C	See individual monographs in the BNF.
16	A	See individual monographs in the BNF.
17	B	See individual monographs in the BNF.
18	A	See GPhC Standards of conduct, ethics and performance, Standards for registered pharmacies, Guidance for Responsible Pharmacists
19	D	See individual monographs in the BNF.
20	A	See BNF page 3 and Guidance for Responsible Pharmacists.
21	C	See BNF Guidance on Prescribing: Controlled Drugs and drug dependence and Dental Practitioners Formulary.
22	E	See individual monographs in BNF.
23	A	See BNF Emergency Treatment of Poisoning Theophylline.
24	B	Medicines, Ethics and Practice The Professional Guide for Pharmacists. Edition

Question	Answer	Guidance
		36 July 2012
25	E	See BNF Section 5.1.4 Aminoglycosides.
26	B	See BNF Section 11.1 Administration of drugs to the eye.
27	C	See BNF Section 2.10.1 Management of stable angina and acute coronary syndromes
28	E	See BNF Section 8.1.1 Alkylating drugs and 8.1.3 Antimetabolites.
29	D	See BNF Guidance on prescribing EEA and Swiss Prescriptions
30	D	See GPhC Standards of conduct, ethics and performance
Calculations section		
31(Calc)	D	28 day supply One day at 6 mg, 14 days at 4 mg and 13 days at 3 mg Using only 1 mg tablets $\therefore 6 + (14 \times 4) + (13 \times 3)$ $= 101$ tablets
32(Calc)	E	Glucose 5% = 5 g in 100 mL $\therefore 25$ g in 500 mL $\therefore 7.5$ g in 150 mL removed leaving 17.5 g Add 150 mL glucose 20% (20 g in 100 mL $\therefore 30$ g in 150 mL) $\therefore 17.5$ g + 30 g in 500 mL $\therefore 9.5$ g in 100 mL = 9.5%
33(Calc)	E	Start 2 days before, in Bangladesh for 21 days and continue for 1 week after leaving = 30 days treatment. Dose for 35 kg child is 3 per day $\therefore 3 \times 30 = 90$
34(Calc)	E	12.5% = 12.5 g in 100 g = 0.125 g in 1g \therefore in 2500 kg = $0.125 \times 2500000 = 312500$ g = 312.5 kg
35(Calc)	B	Ibuprofen 40 mg/kg in 3 divided doses $40 \times 16 \div 3 = 213.3$ mg tds Paracetamol 60 mg/kg daily in 4 divided doses $60 \times 16 \div 4 = 240$ mg qds
36(Calc)	D	BNF section 1.9.4 $4 \times 7 = 28$ capsules in 1 week 1 capsule has 8000 units amylase $\therefore 28 \times 8000$ units in 1 week = 224 000 units
37(Calc)	E	BNF section 2.10.2 Patient weighs 85 kg \therefore total dose of 100 mg

Question	Answer	Guidance
		100 mg = 58.0 million units alteplase
38(Calc)	C	Day 1 4 drops per hour for 6 hours = 24 drops Then 2 drops per hour for 18 hours = 36 drops Day 2 24 drops Day 3 – 21 6 drops per days for 19 days = 114 drops Total = 24 + 36 + 24 + 114 = 198 drops 15 drops = 1 mL ∴ 198 drops = 13.2 mL 1 bottle = 5 mL ∴ need 3 bottles
39(Calc)	D	BNF for Children section 8.2.2 150 micrograms/kg twice daily 150 x 34 x 2 = 10200 micrograms = 10.2 mg ∴ most appropriate dose is 10 mg
40(Calc)	A	Using formula provided, body surface area is 2 m ² Dose 120 mg/m ² = 120 x 2 = 240 mg Each lomustine capsule is 40 mg (BNF section 8.1.1) ∴ each dose requires 6 capsules